Glibenaid M 500 Tablet is a combination oral hypoglycemic agent containing Glibenclamide 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glibenclamide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This dual mechanism addresses both insulin deficiency and insulin resistance, making Glibenaid M 500 effective in patients inadequately controlled by diet and exercise alone or monotherapy. It is prescribed as an adjunct to lifestyle modifications including diet and physical activity. The combination therapy helps in achieving optimal glycemic targets, reducing the risk of diabetes-related complications. Patients should be monitored regularly for blood glucose levels and potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or those undergoing radiologic studies with contrast agents. Glibenaid M 500 should be used under medical supervision, with dose adjustments based on therapeutic response and tolerability to ensure safe and effective diabetes management.